HOTH THERAPEUTICS INC (HOTH) Stock Price & Overview

NASDAQ:HOTH • US44148G2049

Current stock price

0.5619 USD
+0.01 (+2.65%)
At close:
0.58 USD
+0.02 (+3.22%)
After Hours:

The current stock price of HOTH is 0.5619 USD. Today HOTH is up by 2.65%. In the past month the price decreased by -44.37%. In the past year, price decreased by -33.1%.

HOTH Key Statistics

52-Week Range0.5 - 2.115
Current HOTH stock price positioned within its 52-week range.
1-Month Range0.5 - 1.26
Current HOTH stock price positioned within its 1-month range.
Market Cap
8.715M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.90
Dividend Yield
N/A

HOTH Stock Performance

Today
+2.65%
1 Week
-33.02%
1 Month
-44.37%
3 Months
-47.49%
Longer-term
6 Months -64.44%
1 Year -33.10%
2 Years -53.75%
3 Years -67.52%
5 Years -98.51%
10 Years N/A

HOTH Stock Chart

HOTH THERAPEUTICS INC / HOTH Daily stock chart

HOTH Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to HOTH. When comparing the yearly performance of all stocks, HOTH is a bad performer in the overall market: 92.82% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

HOTH Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to HOTH. The financial health of HOTH is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

HOTH Earnings

Next Earnings DateMay 11, 2026
Last Earnings DateMar 27, 2026
PeriodQ4 / 2025
EPS Reported-$0.16
Revenue Reported
EPS Surprise -56.86%
Revenue Surprise %

HOTH Forecast & Estimates

7 analysts have analysed HOTH and the average price target is 5.1 USD. This implies a price increase of 807.63% is expected in the next year compared to the current price of 0.5619.


Analysts
Analysts82.86
Price Target5.1 (807.63%)
EPS Next Y33.13%
Revenue Next YearN/A

HOTH Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership

HOTH Financial Highlights

Over the last trailing twelve months HOTH reported a non-GAAP Earnings per Share(EPS) of -0.9. The EPS increased by 32.33% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-12.47M
Industry RankSector Rank
PM (TTM) N/A
ROA -164%
ROE -202.73%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%50%
Sales Q2Q%N/A
EPS 1Y (TTM)32.33%
Revenue 1Y (TTM)N/A

HOTH Ownership

Ownership
Inst Owners6.36%
Shares15.51M
Float14.96M
Ins Owners3.57%
Short Float %4.5%
Short Ratio1.19

About HOTH

Company Profile

HOTH logo image Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. The company is headquartered in New York City, New York and currently employs 2 full-time employees. The company went IPO on 2019-02-15. The firm is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT), and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The firm also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for obesity, and obesity-related diseases and conditions (HT-VA).

Company Info

IPO: 2019-02-15

HOTH THERAPEUTICS INC

1177 Avenue Of The Americas, 5Th Floor Suite 5066

New York City NEW YORK 10020 US

CEO: Robb Knie

Employees: 2

HOTH Company Website

HOTH Investor Relations

Phone: 16467562997

HOTH THERAPEUTICS INC / HOTH FAQ

What does HOTH do?

Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. The company is headquartered in New York City, New York and currently employs 2 full-time employees. The company went IPO on 2019-02-15. The firm is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT), and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The firm also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for obesity, and obesity-related diseases and conditions (HT-VA).


What is the stock price of HOTH THERAPEUTICS INC today?

The current stock price of HOTH is 0.5619 USD. The price increased by 2.65% in the last trading session.


Does HOTH stock pay dividends?

HOTH does not pay a dividend.


How is the ChartMill rating for HOTH THERAPEUTICS INC?

HOTH has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Should I buy HOTH stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on HOTH.


How many employees does HOTH THERAPEUTICS INC have?

HOTH THERAPEUTICS INC (HOTH) currently has 2 employees.